

S1 Table. Information on the 10 SLE patients and 8 controls from whom plasmablasts were isolated 7 days after influenza vaccination and antibodies were generated

	Subject	Age	Sex ^a	Race ^b	Leuko-/ Lympho-penic ^c	ACR ^d	ANA ^e	Pattern ^f	dsDNA	Ro ^g	La ^g	nRNP ^g	UIL ^h	Rf ⁱ	Immunosuppressive therapy
SLE patients	S1	47	M	W	Y / Y	8	360	NS	-	+	-	+	-	-	Prednisone, Hydroxychloroquine, Mycophenolate mofetil
	S2	33	F	W	N / Y	6	1080	NS	-	+	-	+	-	-	Prednisone, Hydroxychloroquine, Mycophenolate mofetil, Methotrexate
	S3	48	M	W	Y / Y	5	1080	NH	-	+	+	-	-	-	Prednisone, Hydroxychloroquine
	S4	44	F	W	N / N	8	120	NH	+	-	-	-	-	+	Hydroxychloroquine
	S5	43	F	W	Y / N	7	120	NS	-	-	-	-	-	-	Prednisone
	S6	45	M	AA	N / N	5	120	NH	-	-	-	-	-	-	Prednisone, Methotrexate
	S7	31	F	W	N / N	6	180	NH	+	-	-	-	-	-	Prednisone, Hydroxychloroquine, Mycophenolate mofetil
	S8	50	F	W	Y / Y	6	3240	NH	+	+	-	-	-	-	Prednisone, Hydroxychloroquine, Azathioprine
	S9	34	F	W	N / N	4	360	NH	-	+	-	-	-	-	Hydroxychloroquine
	S10	51	F	AA	Y / Y	10	1080	NS	-	-	-	-	+	-	Prednisone, Hydroxychloroquine, Mycophenolate mofetil
Controls	C1	44	M	AA											
	C2	30	F	W											
	C3	29	F	W											
	C4	43	F	W											
	C5	39	F	W											
	C6	29	F	W											
	C7	51	M	W											
	C8	47	F	W											

^aMale (M), Female (F). ^bWestern European descent(W), African-American (AA) ^c Yes(Y), No (N) ^dAmerican College of Rheumatology Criteria for Classification of Systemic Lupus Erythematosus ^eAnti-nuclear antigen (ANA) Titer (1/X) ^fNS: nuclear speckled; NH: nuclear homogenous ^gAutoantibodies against ribonuclearproteins by immunodiffusion ^hUIL (unidentified Line) in which autoantibody specificities are unknown ⁱRheumatoid Factor (anti-IgG)